We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aquestive Therapeutics Inc | NASDAQ:AQST | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.085 | -2.53% | 3.28 | 3.25 | 3.28 | 3.4099 | 3.205 | 3.40 | 1,679,513 | 00:58:51 |
From May 2021 to May 2024
By Chris Wack
Aquestive Therapeutics Inc. shares were up 3% to $3.42 after the company said the U.S. Food and Drug Administration has accepted for filing the resubmission of the New Drug Application for Libervant diazepam Buccal Film for the management of seizure clusters.
The pharmaceutical company said the FDA has assigned a Prescription Drug User Fee Act target goal date of Dec. 23, 2021.
Aquestive said the commercial launch of Libervant, if approved for U.S. market access, would be in the first half of 2022.
Aquestive received a Complete Response Letter from the FDA in September 2020, completed a Type A meeting with the FDA in November 2020 and received further guidance from the FDA in February 2021. The company said it believes that no additional clinical studies will be required for FDA approval of Libervant for U.S. market access.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 19, 2021 10:21 ET (14:21 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Aquestive Therapeutics Chart |
1 Month Aquestive Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
